Stocks of Viking Therapeutics Inc (NASDAQ:VKTX) traded higher last session on Wall Street, up 2.75% to $11.22.
As we calculate the median target price by taking the range between a high of $40.00 and a low of $28.00, we find $34.00. Given the previous closing price of $10.92, this indicates a potential upside of 211.36 percent. VKTX stock price is now -20.61% away from the 50-day moving average and -23.02% away from the 200-day moving average. The market capitalization of the company currently stands at $1.12B.
Brokers who have rated the stock have averaged $33.80 as their price target over the next twelve months.
In other news, Rowland Charles A Jr, Director sold 40,000 shares of the company’s stock on May 16. The stock was sold for $1,000,000 at an average price of $25.00. Upon completion of the transaction, the Director now directly owns 30,000 shares in the company, valued at $0.34 million. An SEC document containing details of the transaction can be found on the SEC’s website. On May 16, Director MACARTNEY LAWSON sold 16,000 shares of the business’s stock. A total of $384,000 was realized by selling the stock at an average price of $24.00. This leaves the insider owning 47,965 shares of the company worth $0.54 million. Insiders disposed of 1,764,159 shares of company stock worth roughly $19.79 million over the past 1 year. A total of 10.16% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in VKTX stock. A new stake in Viking Therapeutics Inc shares was purchased by INVESCO LTD. during the first quarter worth $9,267,000. EVENTIDE ASSET MANAGEMENT, LLC invested $8,415,000 in shares of VKTX during the first quarter. In the first quarter, RHUMBLINE ADVISERS acquired a new stake in Viking Therapeutics Inc valued at approximately $1,434,000. STATE OF NEW JERSEY COMMON PENSION FUND D acquired a new stake in VKTX for approximately $1,224,000. NEUBERGER BERMAN GROUP LLC purchased a new stake in VKTX valued at around $929,000 in the second quarter. In total, there are 246 active investors with 71.72% ownership of the company’s stock.
During the past 12 months, Viking Therapeutics Inc has had a low of $2.59 and a high of $25.72. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 29.63, and a quick ratio of 29.63. The fifty day moving average price for VKTX is $14.13 and a two-hundred day moving average price translates $14.57 for the stock.
The latest earnings results from Viking Therapeutics Inc (NASDAQ: VKTX) was released for Jun, 2023.
Viking Therapeutics Inc(VKTX) Company Profile
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company’s lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
